Taxonomy of Mathematical Modeling Studies for Hepatitis C Among Injection Drug Users

Yaylalı E., Ucler S.

Global Joint Conference on Industrial Engineering and Its Application Areas (GJCIE), ELECTR NETWORK, 14 - 15 August 2020, pp.477-494 identifier

  • Publication Type: Conference Paper / Full Text
  • Doi Number: 10.1007/978-3-030-76724-2_35
  • Page Numbers: pp.477-494
  • Keywords: Mathematical modeling, Taxonomy, Hepatitis C, Injection drug users, Cost-effectiveness analysis, VIRUS TREATMENT, SYRINGE PROGRAMS, HCV TREATMENT, COST-EFFECTIVENESS, ANTIVIRAL TREATMENT, PEOPLE, TRANSMISSION, PREVENTION, IMPACT, PREVALENCE
  • Istanbul Technical University Affiliated: Yes


Hepatitis C (HCV) is one of the significant public health problems, and around 71 million people have chronic Hepatitis C infections globally. Among infected, people who inject drugs (PWID) have an increased risk of transmission, and it is a key risk population. In the last decade, the introduction of direct-acting antivirals (DAA) has started a new era for HCV treatment, and elimination of HCV globally by 2030 became a World Health Organization (WHO) target. Besides clinical and medical studies on HCV infection, modeling and economic studies have been conducted to analyze the spread of this disease, to prevent and eliminate HCV, to determine interventions and programs that are effective and cost-effective, and to optimally allocate resources among high-risk and general populations. In this paper, we survey modeling and cost-effectiveness studies of HCV among injection drug users, and we provide a taxonomy of 73 studies published from 2000 to 2020 that represent 15 countries. We categorized studies based on modeling type, whether it contained cost-effectiveness analysis, the focus of study, and treatment type included. Our taxonomy could be used by modelers, public health policymakers, and researchers to review past HCV models and to develop new models and cost-effectiveness studies.